2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Biological Processes, Pathogenesis, CHIP, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Measurable Residual Disease, ALL, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Real-World Evidence, Study Population, Human, Pediatric, Neonatal
PAPER

3328 High prevalence of leukemia-associated ETV6::RUNX1 fusion positive clones in healthy hispanic newborns

Emily S Tomlinson, MD, Swe Swe Myint2, Adam J de Smith, PhD3, Serine Avagyan, MD, PhD4
1 University of California San Francisco, San Francisco, California, United States
2 Beckman Research Institute of City of Hope, Duarte, California, United States
3 Beckman Research Institute of City of Hope, Duarte, California, United States
4 University of California San Francisco, San Francisco, California, United States

B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood malignancy and is associated with substantial outcome disparities. Despite improved cure rates, children from minoritized populations, particularly those exposed to adverse social determinants of health (aSDOH), experience disproportionately poor outcomes. Hispanic children have a higher incidence of ALL, which is further elevated among those experiencing aSDOH. These disparities underscore the need to define the biologic mechanisms associated with the earliest stages of leukemogenesis in order to identify potentially modifiable risk factors. Preleukemic clones in B-ALL have been traced back to newborn blood spots, indicating an in utero origin and supporting a two-hit model in which postnatal events drive malignant transformation. Up to 6.5% of healthy European newborns harbor the ETV6::RUNX1 (E/R) fusion, a common leukemia-driver alteration, but the prevalence of such clones among Hispanic newborns is unknown. In this study, we sought to determine the prevalence of E/R+ clones in a cohort of healthy Hispanic newborns using an optimized and validated DNA-based assay for sensitive fusion detection in cord blood. Cord blood specimens were obtained from the National Heart, Lung, and Blood Institute’s BioLINCC biorepository. Genomic inverse polymerase chain reaction for exploration of ligated breakpoints (GIPFEL) is based on genomic DNA, which is digested and circularized around SacI sites, enriched around E/R breakpoints. The product is then used in multiplexed quantitative PCR (qPCR) targeting the known SacI ligation sites. Positive samples are demultiplexed, and amplicons are validated through gel electrophoresis and DNA sequencing. We have analyzed 98 of 500 cord blood samples from healthy Hispanic newborns. Among analyzed specimens, E/R+ clones were confirmed in 15, yielding a preliminary prevalence of 15.3%. Of these, most harbored a single unique E/R+ clone, but 7 had two or more unique clones spanning the ETV6 intron 5 and RUNX1 intron 1-2 regions, suggesting independent origins and potential selection of E/R+ preleukemic clones during development.

To better understand potential selection mechanisms underlying these clones, we examined the transcriptional profiles of total hematopoietic cells in the cord blood samples. Bulk RNA sequencing comparing an E/R+ sample and two fusion non-detected samples identified enrichment of interferon signaling, MYC targets, and DNA repair programs, suggesting immune activation alongside proliferative and genotoxic stress. These data establish technical feasibility of using RNA sequencing to investigate transcriptional states in neonatal hematopoiesis as a means to probe fusion-associated states as clues for preleukemic clonal selection and/or persistence.

Overall, we demonstrate feasible detection of E/R+ preleukemic clones in cord blood and identify a preliminary prevalence of 15.3% in a Hispanic newborn cohort, exceeding estimates reported in European cohorts. The exploratory transcriptomic findings support further investigation of perinatal inflammatory signaling within the hematopoietic microenvironment and its relationship to E/R clonal persistence.

Emily S Tomlinson, MD: No relevant conflicts of interest to declare.